Press releases
Apr 13, 2021
Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol
Feb 2, 2021
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
Dec 1, 2020
Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM–002 (S-oxprenolol) for Treating Cancer Cachexia
Nov 23, 2020
Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charité – Universitätsmedizin Berlin
Oct 22, 2020
Actimed Therapeutics to present at upcoming Bio-Europe conference as one of 'Scrip’s 10 to watch'
Sep 2, 2020
Actimed Therapeutics appoints Dr Chika Yoshinaga as Development, Partnering and Financing Advisor in Japan and China
Apr 2, 2020
Actimed Therapeutics appoints Annalisa Jenkins as Advisor
Oct 30, 2019
Actimed Therapeutics appoints Robin Bhattacherjee as CEO
Oct 31, 2018
Actimed Therapeutics, the Cachexia Company, Raises £1.25m in Seed A Round
Apr 5, 2018
Actimed Therapeutics appoints pharma veteran Dr David Ebsworth as Chairman